Chicagoland Metropolitan AsthmaNet Consortium (CMAC)

芝加哥大都会哮喘网络联盟 (CMAC)

基本信息

批准号：
8099543
负责人：
David Gozal
金额：
$ 82.04万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-30 至 2016-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8099543
关键词：
Academic Medical Centers Address Adrenal Cortex Hormones Adult Adult asthma Aftercare Age Agonist Ally Alternaria Ancillary Study Antigens Area Asthma Azithromycin Biocompatible Materials Biological Biological Markers Blood Breathing Bronchoscopy Chicago Child Childhood Childhood Asthma Cities Clinical Clinical Data Clinical Management Clinical Research Clinical Trials Clinical Trials Network Communities Community Networks Coupled DNA Data Development Discipline Dose Education Enrollment Environmental Risk Factor Epidemiology Exhalation Foundations Frequencies Functional disorder Funding Funding Mechanisms Future Genetic Genotype Goals Guidelines HLA G antigen Home environment Hospitals Human Resources Incidence Incubators Industry Inflammation Institution Intervention Leadership Leukotriene Antagonists Lung Lymphocyte MHC antigen Macrolides Major Histocompatibility Complex Malignant Neoplasms Masks Measurement Measures Methodology National Heart, Lung, and Blood Institute Non-Malignant Nose Obstructive Sleep Apnea Outcome Measure Parents Participant Pathogenesis Patients Performance Pharmacodynamics Phase Phase III Clinical Trials Phenotype Population Prevalence Principal Investigator Procedures Qualifying Quality of life RNA Randomized Research Research Design Research Infrastructure Research Personnel Research Project Grants Research Support Resource Development Resources Respiratory physiology Role Safety Salmeterol Sampling Schools Seasons Services Severities Sleep Smoke Smoker Snoring Specimen Structure of parenchyma of lung Symptoms Technology Testing Time Training Support Translational Research United States United States National Institutes of Health Universities Update Work airway inflammation base biobank biomedical resource clinical practice design efficacy testing experience falls human subject improved insight instrument metropolitan montelukast mortality novel primary outcome programs racial and ethnic research study response technology development translational study treatment effect

项目摘要

DESCRIPTION (provided by applicant): This application from the Chicagoland Metropolitan AsthmaNet Consortium (OMAG) is in response to the RFA entitled "Clinical Centers for the NHLBI Asthma Network (AsthmaNet)". The Chicago Metropolitan area has more than 6 million inhabitants who are racially and ethnically diverse. The City of Chicago, which represents about half of this population, has high asthma prevalence rates in both children and adults (exceeding 10% in both groups) and has one of the highest asthma mortality rates in the United States. The CMAC includes academic medical center partners: Northwestern University, the University of Chicago, Children's Memorial Hospital, and John H. Stroger Hospital, and an expansive network of Community Partners. The CMAC is uniquely qualified to participate in AsthmaNet and contribute to the development and successful completion of the network clinical trials and proof of concept/mechanistic studies. This is based on the key personnel having extensive experience in asthma clinical and translational research, including studies exploring its pathophysiology, pathogenesis (genetic and environmental factors), epidemiology and treatment; leadership roles in key research support (including CTSA-funded) programs at their respective institutions; successfully worked together on several asthma research programs: access to a large, diverse asthma population; and successfully enrolled patients and control subjects in NIH, foundation and industry sponsored asthma research studies and clinical trials. The studies proposed address several important issues including: treatment approaches to adult asthmatics who smoke; the role of aggressive pre-treatment in pediatric asthmatics prior to the exacerbation season; the expression of HLA-G, a non-classical MHC antigen, in seasonal asthma exacerbations; and the incidence of obstructive sleep apnea (OSA) in asthmatic children and whether treatment of OSA improves asthma symptoms, quality of life and lung function. Participation by the CMAC will strengthen AsthmaNet and increase the likelihood that it will achieve its goal to address the most important asthma management questions and new treatment approaches in pediatric and adult asthma and inform clinical practice and future updates to the NAEPP guidelines.

描述（由申请人提供）：芝加哥大都会哮喘网络联盟 (OMAG) 的这份申请是对题为“NHLBI 哮喘网络临床中心 (AsthmaNet)”的 RFA 的回应。芝加哥大都市区拥有超过 600 万居民，他们是不同种族和民族的。芝加哥市约占该人口的一半，儿童和成人的哮喘患病率都很高（两组均超过 10%），并且是美国哮喘死亡率最高的城市之一。 CMAC 包括学术医疗中心合作伙伴：西北大学、芝加哥大学、儿童纪念医院和约翰·H·斯特罗格医院，以及广泛的社区合作伙伴网络。 CMAC 具有参与 AsthmaNet 的独特资格，并为网络临床试验和概念验证/机制研究的开发和成功完成做出贡献。这是基于关键人员在哮喘临床和转化研究方面拥有丰富的经验，包括探索其病理生理学、发病机制（遗传和环境因素）、流行病学和治疗的研究；在各自机构的关键研究支持（包括 CTSA 资助的）项目中发挥领导作用；成功地合作开展了多个哮喘研究项目：接触大量、多样化的哮喘人群；并成功地将患者和对照受试者纳入 NIH、基金会和行业赞助的哮喘研究和临床试验。拟议的研究解决了几个重要问题，包括：吸烟成年哮喘患者的治疗方法；在小儿哮喘发作季节之前进行积极的预处理的作用； HLA-G（一种非经典 MHC 抗原）在季节性哮喘恶化中的表达；哮喘儿童阻塞性睡眠呼吸暂停 (OSA) 的发生率，以及 OSA 治疗是否可以改善哮喘症状、生活质量和肺功能。 CMAC 的参与将加强 AsthmaNet 并增加其实现其目标的可能性，即解决最重要的哮喘管理问题和儿童和成人哮喘的新治疗方法，并为临床实践和 NAEPP 指南的未来更新提供信息。